Abdalhakim Shubietah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abdalhakim Shubietah has a total of 255 co-authors. Here are the top co-authors by number of shared publications:
- Ameer Awashra
Department of Medicine, An Najah National University, Nablus, Palestine
25 shared publications - Mohamed Salah Elgendy
Faculty of Medicine, Tanta University, Tanta, Egypt
21 shared publications - Ahmed Emara
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
14 shared publications - Mohammed AbuBaha
Department of Medicine, An-Najah National University, Nablus, Palestine
11 shared publications - Islam Rajab
Department of Medicine, Faculty of Medicine and Health Sciences An‐Najah National University Nablus Palestine
9 shared publications - Anwar Zahran
Department of Medicine, Faculty of Medicine and Health Sciences An‐Najah National University Nablus Palestine
7 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Timing of Catheter Ablation After Heart Failure Diagnosis for Atrial Fibrillation: A Propensity‐Score‐Matched Analysis
Background: Catheter ablation improves outcomes in patients with atrial fibrillation (AF) and heart failure (HF). However, most of the evidence on the importance of ablation timing has been anchored to AF rather than HF onset, leaving the optimal interval between HF diagnosis and ablation incompletely defined. Objectives: To evaluate the association between the timing of catheter ablation following the first diagnosis of HF and subsequent clinical outcomes in patients with established AF. Methods: We performed a retrospective propensity‐score‐matched cohort study using the TriNetX Research Network. Adults (≥18 years) with AF who subsequently developed HF and underwent catheter ablation were included. The primary analysis compared ablation from day 1 through 3 months after HF diagnosis with ablation at least 91 days after HF diagnosis. Propensity‐score matching yielded 2,570 patients in each group. Outcomes were assessed for 2 years after ablation and included all‐cause mortality, electrical cardioversion, emergency department or inpatient encounters, and HF exacerbation. A 1‐year timing threshold and analyses stratified by recorded left ventricular ejection fraction were examined as sensitivity analyses. Results: Mean follow‐up was 549.3±253.2 days after early ablation and 534.1±255.3 days after later ablation. Mortality was similar between groups (11.0% vs 10.0%; hazard ratio [HR] 1.078, 95% confidence interval [CI] 0.910–1.276; p = 0.384), as were emergency department or inpatient encounters (66.2% vs 65.6%; HR 1.006, 95% CI 0.940–1.076; p = 0.865). Early ablation was associated with fewer cardioversions (15.0% vs 18.6%; HR 0.788, 95% CI 0.689–0.901; p < 0.001) and fewer HF exacerbation events (39.5% vs 46.0%; HR 0.824, 95% CI 0.758–0.896; p < 0.001). The 1‐year timing analysis showed a similar pattern for cardioversion and the HF exacerbation. Conclusions: Among patients with AF and HF who ultimately underwent ablation, ablation within 3 months of HF diagnosis was associated with fewer subsequent cardioversions and HF exacerbations than ablation performed from day 91 onward. However, there was no significant difference in mortality between the two cohorts. These findings identify the first months after HF diagnosis as a clinically relevant period for reassessing rhythm‐control strategy and warrant prospective evaluation of ablation timing after HF recognition.
- 12 October 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Timing of Catheter Ablation After Heart Failure Diagnosis for Atrial Fibrillation: A Propensity‐Score‐Matched Analysis
Background: Catheter ablation improves outcomes in patients with atrial fibrillation (AF) and heart failure (HF). However, most of the evidence on the importance of ablation timing has been anchored to AF rather than HF onset, leaving the optimal interval between HF diagnosis and ablation incompletely defined. Objectives: To evaluate the association between the timing of catheter ablation following the first diagnosis of HF and subsequent clinical outcomes in patients with established AF. Methods: We performed a retrospective propensity‐score‐matched cohort study using the TriNetX Research Network. Adults (≥18 years) with AF who subsequently developed HF and underwent catheter ablation were included. The primary analysis compared ablation from day 1 through 3 months after HF diagnosis with ablation at least 91 days after HF diagnosis. Propensity‐score matching yielded 2,570 patients in each group. Outcomes were assessed for 2 years after ablation and included all‐cause mortality, electrical cardioversion, emergency department or inpatient encounters, and HF exacerbation. A 1‐year timing threshold and analyses stratified by recorded left ventricular ejection fraction were examined as sensitivity analyses. Results: Mean follow‐up was 549.3±253.2 days after early ablation and 534.1±255.3 days after later ablation. Mortality was similar between groups (11.0% vs 10.0%; hazard ratio [HR] 1.078, 95% confidence interval [CI] 0.910–1.276; p = 0.384), as were emergency department or inpatient encounters (66.2% vs 65.6%; HR 1.006, 95% CI 0.940–1.076; p = 0.865). Early ablation was associated with fewer cardioversions (15.0% vs 18.6%; HR 0.788, 95% CI 0.689–0.901; p < 0.001) and fewer HF exacerbation events (39.5% vs 46.0%; HR 0.824, 95% CI 0.758–0.896; p < 0.001). The 1‐year timing analysis showed a similar pattern for cardioversion and the HF exacerbation. Conclusions: Among patients with AF and HF who ultimately underwent ablation, ablation within 3 months of HF diagnosis was associated with fewer subsequent cardioversions and HF exacerbations than ablation performed from day 91 onward. However, there was no significant difference in mortality between the two cohorts. These findings identify the first months after HF diagnosis as a clinically relevant period for reassessing rhythm‐control strategy and warrant prospective evaluation of ablation timing after HF recognition.
- 23 September 2026
- Published by Wiley in Nephrology
- Vol. 31 (10)
FGF23 –Klotho Axis Dysregulation in Type 4 Cardiorenal Syndrome: Molecular Mechanisms, Paediatric Perspectives, and Emerging Therapeutic Targets
Cardiorenal syndrome (CRS) represents a bidirectional interplay between cardiac and renal dysfunction, but CRS cases involving paediatric patients represent only a minority of cases overall. CRS type‐4 (CRS4), a long‐term reno‐cardiac syndrome driven by chronic kidney disease (CKD), is not the most frequently reported subtype in paediatric cohorts, where type 1 CRS predominates (1); it is, however, the subtype most relevant to children with established CKD and the one in which FGF23–α‐Klotho signalling is most directly implicated. Beyond traditional haemodynamic and neurohormonal mechanisms, dysregulation of the fibroblast growth factor 23 (FGF23)–α‐Klotho axis has emerged as a pivotal molecular contributor to the pathophysiology of CRS. FGF23, primarily secreted by osteocytes, regulates phosphate and vitamin D homeostasis via fibroblast growth factor receptors in concert with the co‐receptor α‐Klotho; however, the cardiac hypertrophic actions of FGF23 in CRS are mediated through FGFR4 and do not require α‐Klotho. In CKD, early α‐Klotho deficiency leads to FGF23 resistance, hyperphosphatemia, and maladaptive cardiovascular remodelling, including left‐ventricular hypertrophy and vascular calcification. These alterations are compounded by inflammation, activation of the renin‐angiotensin‐aldosterone system, and iron deficiency, all of which can modulate FGF23 expression and signalling. Experimental and clinical evidence implicates this axis in both renal injury progression and direct cardiac toxicity, with distinct physiological considerations in paediatric populations due to developmental variations in bone turnover, mineral metabolism, and elevated baseline phosphate flux. This review highlights paediatric‐specific gaps, synthesizes current mechanistic insights, and assesses how emerging targeted strategies such as phosphate restriction might be tailored to paediatric CRS4 rather than being extrapolated from adult CKD populations. Standardization of biomarker assays and longitudinal paediatric studies remains critical for translating these molecular insights into early diagnostic tools and targeted interventions in CRS.
- 23 September 2026
- Published by Wiley in Nephrology
- Vol. 31 (10)
FGF23 –Klotho Axis Dysregulation in Type 4 Cardiorenal Syndrome: Molecular Mechanisms, Paediatric Perspectives, and Emerging Therapeutic Targets
Cardiorenal syndrome (CRS) represents a bidirectional interplay between cardiac and renal dysfunction, but CRS cases involving paediatric patients represent only a minority of cases overall. CRS type‐4 (CRS4), a long‐term reno‐cardiac syndrome driven by chronic kidney disease (CKD), is not the most frequently reported subtype in paediatric cohorts, where type 1 CRS predominates (1); it is, however, the subtype most relevant to children with established CKD and the one in which FGF23–α‐Klotho signalling is most directly implicated. Beyond traditional haemodynamic and neurohormonal mechanisms, dysregulation of the fibroblast growth factor 23 (FGF23)–α‐Klotho axis has emerged as a pivotal molecular contributor to the pathophysiology of CRS. FGF23, primarily secreted by osteocytes, regulates phosphate and vitamin D homeostasis via fibroblast growth factor receptors in concert with the co‐receptor α‐Klotho; however, the cardiac hypertrophic actions of FGF23 in CRS are mediated through FGFR4 and do not require α‐Klotho. In CKD, early α‐Klotho deficiency leads to FGF23 resistance, hyperphosphatemia, and maladaptive cardiovascular remodelling, including left‐ventricular hypertrophy and vascular calcification. These alterations are compounded by inflammation, activation of the renin‐angiotensin‐aldosterone system, and iron deficiency, all of which can modulate FGF23 expression and signalling. Experimental and clinical evidence implicates this axis in both renal injury progression and direct cardiac toxicity, with distinct physiological considerations in paediatric populations due to developmental variations in bone turnover, mineral metabolism, and elevated baseline phosphate flux. This review highlights paediatric‐specific gaps, synthesizes current mechanistic insights, and assesses how emerging targeted strategies such as phosphate restriction might be tailored to paediatric CRS4 rather than being extrapolated from adult CKD populations. Standardization of biomarker assays and longitudinal paediatric studies remains critical for translating these molecular insights into early diagnostic tools and targeted interventions in CRS.
- 5 September 2026
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 43 (5) , 47
Cardiac metastases from colorectal cancer: a comprehensive systematic review of clinical presentation, cardiac involvement, and outcomes
- 5 September 2026
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 43 (5) , 47
Cardiac metastases from colorectal cancer: a comprehensive systematic review of clinical presentation, cardiac involvement, and outcomes
- Open Access
- 18 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (9) , 103147
Confounding by Indication, Temporal Alignment, and Coding Bias in Frail Patients After Alcohol Septal Ablation
- 18 August 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (9) , 103147
Open AccessConfounding by Indication, Temporal Alignment, and Coding Bias in Frail Patients After Alcohol Septal Ablation
- Open Access
- 23 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (6) , ztag105
Electronic health records research: easy evidence, harder oversight
Electronic health record (EHR) research networks have accelerated clinical research by making it possible to study large and diverse patient populations over time. However, the quality and resources required for these studies vary widely, depending on whether they rely on simple aggregate outputs or a more rigorous patient-level data, a central but occasionally unstated distinction in EHR-based research. Patient-level data can support a more reproducible cohort construction, time-anchored exposure definitions, and more precise outcome ascertainment, whereas aggregate approaches limit rigour regarding the precise definition of index dates, the completeness of covariate capture, the accurate characterization of medication exposure windows, and the validity of outcome ascertainment. These limitations may amplify well-known threats to causal inference in observational research, including misclassification, incomplete outcome capture across health systems, residual confounding, and immortal time bias, particularly when comparative effectiveness questions are pursued. In this viewpoint, we outline why ‘easy evidence’ can yield fragile conclusions when analytic granularity is limited, and we propose pragmatic expectations for reporting and review: explicit declaration of data level (patient vs. aggregate), clear time-zero definitions for all arms, validated case-definition algorithms when available, sensitivity analyses aligned with plausible misclassification, and transparency sufficient to enable reproducibility. Strengthening methodological norms is essential to preserve the credibility of EHR-based evidence as its influence on clinical discourse continues to grow.
- 23 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 7 (6) , ztag105
Open AccessElectronic health records research: easy evidence, harder oversight
Electronic health record (EHR) research networks have accelerated clinical research by making it possible to study large and diverse patient populations over time. However, the quality and resources required for these studies vary widely, depending on whether they rely on simple aggregate outputs or a more rigorous patient-level data, a central but occasionally unstated distinction in EHR-based research. Patient-level data can support a more reproducible cohort construction, time-anchored exposure definitions, and more precise outcome ascertainment, whereas aggregate approaches limit rigour regarding the precise definition of index dates, the completeness of covariate capture, the accurate characterization of medication exposure windows, and the validity of outcome ascertainment. These limitations may amplify well-known threats to causal inference in observational research, including misclassification, incomplete outcome capture across health systems, residual confounding, and immortal time bias, particularly when comparative effectiveness questions are pursued. In this viewpoint, we outline why ‘easy evidence’ can yield fragile conclusions when analytic granularity is limited, and we propose pragmatic expectations for reporting and review: explicit declaration of data level (patient vs. aggregate), clear time-zero definitions for all arms, validated case-definition algorithms when available, sensitivity analyses aligned with plausible misclassification, and transparency sufficient to enable reproducibility. Strengthening methodological norms is essential to preserve the credibility of EHR-based evidence as its influence on clinical discourse continues to grow.
- Open Access
- 18 June 2026
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 20
Clinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data
Background: Pulmonary arterial hypertension (PAH) remains progressive despite contemporary background therapy. Sotatercept is a novel activin signaling inhibitor that targets pulmonary vascular remodeling and may improve clinical and hemodynamic outcomes. Objectives: To evaluate the efficacy, hemodynamic effects, and safety of sotatercept in patients with PAH. Design: Systematic review and meta-analysis of randomized controlled trials (RCTs). Data sources and methods: Five electronic databases were searched through October 2, 2025, for eligible RCTs. Time-to-event outcomes were analyzed using pooled individual patient data with hazard ratios (HRs), while secondary outcomes were assessed using random-effects risk ratios (RRs) and mean differences (MDs), with 95% confidence intervals (CI). Trial-sequential analysis (TSA) evaluated the conclusiveness of results. Results: In four RCTs ( n = 889), sotatercept reduced clinical worsening or death by 77% (HR 0.23, 95% CI 0.16–0.32, p < 0.001) and prolonged event-free survival by ~40 weeks. World Health Organization (WHO) functional class improved in 40.3% vs 24.3% (RR 1.71, 95% CI 1.32–2.21), and 6-minute walk distance increased by MD 30.27 m (95% CI 13.45–47.08), while pulmonary vascular resistance (PVR) declined significantly (MD −247 dyn·s·cm– 5 , 95% CI −301.7; −192.2). Serious adverse events were slightly less frequent with sotatercept (26.2% vs 31.7%, RR 0.83); however, total bleeding (37.9% vs 18.7%, RR 2.00), epistaxis (26.7% vs 5.4%, RR 4.89), and telangiectasia (19.8% vs 6.4%, RR 3.24) were more common. TSA revealed conclusiveness in clinical worsening, WHO functional class, and PVR, as well as increases in bleeding events and epistaxis. Conclusion: Sotatercept significantly improves clinical outcomes and extends event-free survival in PAH, with an acceptable safety profile; however, caution is warranted regarding bleeding events. These results support its role as an add-on therapy in PAH management. Trial registration: PROSPERO ID: CRD420251166414.
- 18 June 2026
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 20
Open AccessClinical, hemodynamic, and safety outcomes of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized trials with time-to-event data
Background: Pulmonary arterial hypertension (PAH) remains progressive despite contemporary background therapy. Sotatercept is a novel activin signaling inhibitor that targets pulmonary vascular remodeling and may improve clinical and hemodynamic outcomes. Objectives: To evaluate the efficacy, hemodynamic effects, and safety of sotatercept in patients with PAH. Design: Systematic review and meta-analysis of randomized controlled trials (RCTs). Data sources and methods: Five electronic databases were searched through October 2, 2025, for eligible RCTs. Time-to-event outcomes were analyzed using pooled individual patient data with hazard ratios (HRs), while secondary outcomes were assessed using random-effects risk ratios (RRs) and mean differences (MDs), with 95% confidence intervals (CI). Trial-sequential analysis (TSA) evaluated the conclusiveness of results. Results: In four RCTs ( n = 889), sotatercept reduced clinical worsening or death by 77% (HR 0.23, 95% CI 0.16–0.32, p < 0.001) and prolonged event-free survival by ~40 weeks. World Health Organization (WHO) functional class improved in 40.3% vs 24.3% (RR 1.71, 95% CI 1.32–2.21), and 6-minute walk distance increased by MD 30.27 m (95% CI 13.45–47.08), while pulmonary vascular resistance (PVR) declined significantly (MD −247 dyn·s·cm– 5 , 95% CI −301.7; −192.2). Serious adverse events were slightly less frequent with sotatercept (26.2% vs 31.7%, RR 0.83); however, total bleeding (37.9% vs 18.7%, RR 2.00), epistaxis (26.7% vs 5.4%, RR 4.89), and telangiectasia (19.8% vs 6.4%, RR 3.24) were more common. TSA revealed conclusiveness in clinical worsening, WHO functional class, and PVR, as well as increases in bleeding events and epistaxis. Conclusion: Sotatercept significantly improves clinical outcomes and extends event-free survival in PAH, with an acceptable safety profile; however, caution is warranted regarding bleeding events. These results support its role as an add-on therapy in PAH management. Trial registration: PROSPERO ID: CRD420251166414.
- Open Access
- 18 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (5) , e72398
Genotype–Phenotype Discordance in Cardiomyopathies: Pathophysiology, Clinical Expression, and Therapeutic Considerations
Background: Cardiomyopathies encompass a spectrum of myocardial disorders often attributed to underlying genetic mutations. However, genotype–phenotype discordance where the genetic profile does not align with the expected clinical presentation poses significant diagnostic, prognostic, and therapeutic challenges. Objective: To review the mechanisms underlying genotype–phenotype discordance in cardiomyopathies, explore its clinical implications, and propose future research directions to bridge the gap between molecular findings and patient outcomes. Methods: A narrative review was conducted using PubMed, Scopus, and Embase for articles published between 2000 and 2025. Search terms included “genotype‐phenotype discordance”, “cardiomyopathy”, “penetrance”, “expressivity”, “modifier genes”, and “epigenetics”. Included studies focused on genetic and clinical variability in hypertrophic, dilated, arrhythmogenic, and restrictive cardiomyopathies. Priority was given to cohort studies, family‐based analyses, and mechanistic investigations addressing epigenetic, polygenic, and environmental contributors to phenotypic heterogeneity. Results: Multiple factors contribute to genotype–phenotype discordance in cardiomyopathies, including incomplete penetrance, variable expressivity, epigenetic regulation, modifier genes, and environmental influences such as exercise and comorbidities. This discordance complicates risk stratification and personalized therapy. Clinically, individuals with pathogenic variants may remain asymptomatic, while others without identified mutations may exhibit overt disease. Emerging tools such as polygenic risk scores, multi‐omics integration, and longitudinal phenotyping are improving phenotype prediction. Conclusion: Genotype–phenotype discordance in cardiomyopathies underscores the complexity of translating genetic insights into clinical practice. A multidimensional approach combining genetic, molecular, and environmental data is essential to refine diagnosis, guide management, and inform genetic counseling. Future research should focus on deep phenotyping, systems biology, and longitudinal cohort studies to unravel the dynamic interplay between genes and environment.
- 18 May 2026
- Published by Wiley in Health Science Reports
- Vol. 9 (5) , e72398
Open AccessGenotype–Phenotype Discordance in Cardiomyopathies: Pathophysiology, Clinical Expression, and Therapeutic Considerations
Background: Cardiomyopathies encompass a spectrum of myocardial disorders often attributed to underlying genetic mutations. However, genotype–phenotype discordance where the genetic profile does not align with the expected clinical presentation poses significant diagnostic, prognostic, and therapeutic challenges. Objective: To review the mechanisms underlying genotype–phenotype discordance in cardiomyopathies, explore its clinical implications, and propose future research directions to bridge the gap between molecular findings and patient outcomes. Methods: A narrative review was conducted using PubMed, Scopus, and Embase for articles published between 2000 and 2025. Search terms included “genotype‐phenotype discordance”, “cardiomyopathy”, “penetrance”, “expressivity”, “modifier genes”, and “epigenetics”. Included studies focused on genetic and clinical variability in hypertrophic, dilated, arrhythmogenic, and restrictive cardiomyopathies. Priority was given to cohort studies, family‐based analyses, and mechanistic investigations addressing epigenetic, polygenic, and environmental contributors to phenotypic heterogeneity. Results: Multiple factors contribute to genotype–phenotype discordance in cardiomyopathies, including incomplete penetrance, variable expressivity, epigenetic regulation, modifier genes, and environmental influences such as exercise and comorbidities. This discordance complicates risk stratification and personalized therapy. Clinically, individuals with pathogenic variants may remain asymptomatic, while others without identified mutations may exhibit overt disease. Emerging tools such as polygenic risk scores, multi‐omics integration, and longitudinal phenotyping are improving phenotype prediction. Conclusion: Genotype–phenotype discordance in cardiomyopathies underscores the complexity of translating genetic insights into clinical practice. A multidimensional approach combining genetic, molecular, and environmental data is essential to refine diagnosis, guide management, and inform genetic counseling. Future research should focus on deep phenotyping, systems biology, and longitudinal cohort studies to unravel the dynamic interplay between genes and environment.
- 17 May 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (2) , 357-375
Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications
Renal denervation (RDN) is a minimally invasive technique that disrupts renal sympathetic nerve activity, reducing sympathetic overdrive implicated in hypertension and other cardiovascular disorders. After early enthusiasm waned following SYMPLICITY HTN‐3, subsequent rigorously designed trials re‐established its efficacy. This review summarizes mechanistic insights, clinical evidence, and emerging applications of RDN. Data from randomized trials, meta‐analyses, registries, and translational studies were evaluated to assess their safety, efficacy, and broader therapeutic potential. Recent trials (SPYRAL HTN‐OFF MED, RADIANCE HTN‐TRIO, RADIANCE II) show consistent and durable systolic blood pressure reductions of approximately 5–10 mmHg with excellent safety. Beyond resistant hypertension, preliminary studies suggest benefits in heart failure (HFrEF and HFpEF), atrial fibrillation when combined with pulmonary vein isolation, chronic kidney disease, and metabolic syndrome. Mechanistic data reveal improved autonomic balance, regression of left ventricular hypertrophy, and possible renal protection. Limitations include procedural variability, incomplete nerve ablation, and the lack of large outcome‐based cardiovascular trials. Nevertheless, cost‐effectiveness analyses and recent ESC (2024) and AHA/ACC (2025) guidelines endorse RDN as a reasonable adjunct for resistant or uncontrolled hypertension. RDN offers sustained blood pressure control with a strong safety profile. Its expanding role across cardiovascular conditions positions it as a promising adjunctive therapy. Future outcome‐driven studies and standardized procedural approaches are needed to refine its place in clinical practice.
- 17 May 2026
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (2) , 357-375
Renal Denervation in Cardiovascular Diseases: Mechanisms, Evidence, and Expanding Applications
Renal denervation (RDN) is a minimally invasive technique that disrupts renal sympathetic nerve activity, reducing sympathetic overdrive implicated in hypertension and other cardiovascular disorders. After early enthusiasm waned following SYMPLICITY HTN‐3, subsequent rigorously designed trials re‐established its efficacy. This review summarizes mechanistic insights, clinical evidence, and emerging applications of RDN. Data from randomized trials, meta‐analyses, registries, and translational studies were evaluated to assess their safety, efficacy, and broader therapeutic potential. Recent trials (SPYRAL HTN‐OFF MED, RADIANCE HTN‐TRIO, RADIANCE II) show consistent and durable systolic blood pressure reductions of approximately 5–10 mmHg with excellent safety. Beyond resistant hypertension, preliminary studies suggest benefits in heart failure (HFrEF and HFpEF), atrial fibrillation when combined with pulmonary vein isolation, chronic kidney disease, and metabolic syndrome. Mechanistic data reveal improved autonomic balance, regression of left ventricular hypertrophy, and possible renal protection. Limitations include procedural variability, incomplete nerve ablation, and the lack of large outcome‐based cardiovascular trials. Nevertheless, cost‐effectiveness analyses and recent ESC (2024) and AHA/ACC (2025) guidelines endorse RDN as a reasonable adjunct for resistant or uncontrolled hypertension. RDN offers sustained blood pressure control with a strong safety profile. Its expanding role across cardiovascular conditions positions it as a promising adjunctive therapy. Future outcome‐driven studies and standardized procedural approaches are needed to refine its place in clinical practice.